Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 2/20 | 0.42 |
| ▸ | HTR2C | P28335 | 3/20 | 0.40 |
| ▸ | DRD2 | P14416 | 3/20 | 0.40 |
| ▸ | HTR2B | P41595 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 5/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1122055 | 1.00 | SRD5A2 (0.42) | SRD5A2HTR2CDRD2HTR2BHTR2A | |
| SCHEMBL20368726 | 1.00 | SRD5A2 (0.42) | SRD5A2HTR2CDRD2HTR2BHTR2A | |
| SCHEMBL13262372 | 0.98 | SRD5A2 (0.42) | SRD5A2HTR2CDRD2HTR2BHTR2A | |
| SCHEMBL20368725 | 0.98 | SRD5A2 (0.42) | SRD5A2HTR2CDRD2HTR2BHTR2A | |
| SCHEMBL12618690 | 0.96 | SRD5A2 (0.37) | SRD5A2HTR2CDRD2HTR2BHTR2A | |
| SCHEMBL12352790 | 0.94 | SRD5A2 (0.42) | SRD5A2HTR2CDRD2HTR2BHTR2A | |
| SCHEMBL178330 | 0.94 | SRD5A2 (0.42) | SRD5A2HTR2CDRD2HTR2BHTR2A | |
| SCHEMBL20364749 | 0.93 | SRD5A2 (0.40) | SRD5A2HTR2CDRD2HTR2BHTR2A | |
| SCHEMBL383954 | 0.92 | SRD5A2 (0.38) | SRD5A2HTR2CDRD2HTR2BHTR2A | |
| SCHEMBL18820714 | 0.92 | SRD5A2 (0.38) | SRD5A2HTR2CDRD2HTR2BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 213 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3189083-B2 | POLYCYCLIC PHOTOINITIATORS | IGM GROUP B V (NL) | 2023-07-05 | — | — | EP | disclosed |
| CN-107207456-B | Latent acids and their use | 巴斯夫欧洲公司 | 2021-05-04 | — | — | CN | disclosed |
| EP-3253735-B1 | LATENT ACIDS AND THEIR USE | BASF SE (DE) | 2021-03-31 | — | — | EP | disclosed |
| US-10838302-B2 | Cross-linkable fluorinated photopolymer | ORTHOGONAL, INC. (US) | 2020-11-17 | — | — | US | disclosed |
| CN-107251190-B | Lithographic patterning of electronic devices | 正交公司 | 2020-11-10 | — | — | CN | disclosed |
| CN-109790137-B | Polycyclic glyoxylic acid esters as photoinitiators | IGM集团公司 | 2020-10-30 | — | — | CN | disclosed |
| EP-3507279-B1 | POLYCYCLIC GLYOXYLATES AS PHOTOINITIATORS | IGM GROUP B V (NL) | 2020-10-14 | — | — | EP | disclosed |
| US-20200301276-A1 | CROSS-LINKABLE FLUORINATED PHOTOPOLYMER | ORTHOGONAL, INC. (US) | 2020-09-24 | — | — | US | disclosed |
| WO-2020163762-A1 | FLUOROPOLYMER RESIST STRUCTURES HAVING AN UNDERCUT PROFILE | ORTHOGONAL, INC. (US) | 2020-08-13 | — | — | WO | disclosed |
| US-10739680-B2 | Cross-linkable fluorinated photopolymer | ORTHOGONAL, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20080311515-A1 | POSITIVE RESIST COMPOSITION AND METHOD OF FORMING RESIST PATTERN | TOKYO OHKA KOGYO CO., LTD. (JP) | 2008-12-18 | — | — | US | disclosed |
| US-20080292988-A1 | RESIST COMPOSITION AND METHOD OF FORMING RESIST PATTERN | TOKYO OHKA KOGYO CO., LTD (JP) | 2008-11-27 | — | — | US | disclosed |
| US-20080268376-A1 | POSITIVE RESIST COMPOSITION FOR IMMERSION EXPOSURE, METHOD OF FORMING RESIST PATTERN, AND FLUORINE-CONTAINING POLYMERIC COMPOUND | TOKYO OHKA KOGYO CO., LTD. (JP) | 2008-10-30 | — | — | US | disclosed |
| US-20080248422-A1 | RESIST COMPOSITION, METHOD OF FORMING RESIST PATTERN, COMPOUND AND ACID GENERATOR | TOKYO OHKA KOGYO CO., LTD. (JP) | 2008-10-09 | — | — | US | disclosed |
| US-7399577-B2 | Halogenated oxime derivatives and the use thereof | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 2008-07-15 | — | — | US | disclosed |
| US-20080145784-A1 | Positive Resist Composition, Method For Resist Pattern Formation and Compound | TOKYO OHKA KOGYO CO., LTD. (JP) | 2008-06-19 | — | — | US | disclosed |
| US-20080090171-A1 | POSITIVE RESIST COMPOSITION FOR IMMERSION LITHOGRAPHY AND METHOD FOR FORMING RESIST PATTERN | TOKYO OHKA KOGYO CO., LTD. (JP) | 2008-04-17 | — | — | US | disclosed |
| WO-2008022952-A1 | UV-DOSIS INDICATORS | CIBA HOLDING INC. (CH) | 2008-02-28 | — | — | WO | disclosed |
| WO-2007147782-A2 | OXIME SULFONATES AND THE USE THEROF AS LATENT ACIDS | CIBA HOLDING INC. (CH) | 2007-12-27 | — | — | WO | disclosed |
| EP-1772479-A1 | Silicon coated release substrate | Ciba Specialty Chemicals Holding Inc. (CH) | 2007-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080248422-A1 | RESIST COMPOSITION, METHOD OF FORMING RESIST PATTERN, COMPOUND AND ACID GENERATOR | RER1, ACAD9, RRS1 | SRD5A2 2923/4885HTR2C 4139/4885DRD2 1853/4885 |
| US-20080145784-A1 | Positive Resist Composition, Method For Resist Pattern Formation and Compound | POLR1A, POLR2A, POLR2B | SRD5A2 2710/4885HTR2C 1529/4885DRD2 334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.